Deals channel feed

Re­gen­eron buys Art Krieg’s biotech start­up for a dis­count price, boost­ing I/O pipeline

4 years ago
R&D

Hit by 2 more flops, Bris­tol My­ers and Nek­tar wind down IL-2/PD-1 pro­gram at the cen­ter of $3.6B deal

4 years ago

Tiny Ok­la­homa com­pa­ny gets the eye of Boehringer In­gel­heim, sign­ing deal for re­gen­er­a­tive hear­ing loss treat­ment

4 years ago
Startups
R&D

In bid to re­make it­self af­ter pan­cre­at­ic can­cer flop, Halozyme ac­quires Antares and its drug de­liv­ery tech for $960M

4 years ago

From $3M to $1.9B: Glax­o­SmithK­line in­serts dis­card­ed Gilead drug in­to late-stage port­fo­lio, buy­ing out the turn­around crew at Sier­ra

4 years ago

Backed by bil­lion­aire Mike Platt, En­gi­tix scores an­oth­er deal with Take­da to go af­ter IBD

4 years ago
Startups

BioN­Tech to ex­plore po­ten­tial of de­liv­er­ing mR­NA vac­cines oral­ly with new part­ner

4 years ago
R&D
Pharma

Stealth UK biotech in-li­cens­es Lil­ly can­di­dates in pur­suit of 'in­hibit­ing the in­hibitor' in car­dio­vas­cu­lar dis­ease

4 years ago
R&D

Can a with­drawn Eli Lil­ly drug find sec­ond life in ra­dio­phar­ma? Lit­tle biotech hands over $5M cash to find out

4 years ago

Car­lyle vaults in­to biotech in­vest­ing, buy­ing Abing­worth and launch­ing a new com­pa­ny aimed at piv­otal leaps

4 years ago

Af­ter tak­ing a $73M hit, J&J part­ner Gen­mab los­es ar­bi­tra­tion over roy­al­ties on megablock­buster Darza­lex

4 years ago
Pharma
Law

Neu­ro play­er Jazz Phar­ma­ceu­ti­cals dives in­to im­muno-on­col­o­gy, ink­ing cy­tokine pact with Were­wolf

4 years ago

Surg­ing ahead in the RSV race, Pfiz­er buys out a PhII play­er in $525M M&A pact

4 years ago

Spot­ting a gem from transpa­cif­ic biotech, As­traZeneca pays $25M cash to pick up a pre­clin­i­cal bis­pe­cif­ic an­ti­body

4 years ago
China

Build­ing on its reti­nal dis­ease ex­per­tise, Re­gen­eron signs eye-fo­cused gene ther­a­py pact with Ger­man biotech

4 years ago

Glax­o­SmithK­line keeps truck­ing along­side AI with new, mul­ti-year pathol­o­gy part­ner­ship with Boston out­fit

4 years ago
AI

Mukher­jee and Vale's Myeloid teams up with David Li­u's Prime Med­i­cine in race against Tessera

4 years ago
Startups
R&D

Pe­ter Thiel's Mithril leads ef­fort to elect a new slate of in­sid­ers to the board of trou­bled Covid play­er Ada­gio

4 years ago
People

Roche's Chugai lines up a $185M deal to switch drug can­di­date to sub­cu­ta­neous for­mu­la­tion

4 years ago

Ama­zon jumps in­to de­cen­tral­ized tri­als push as AWS part­ners with start­up to cut down on in­ef­fi­cien­cies

4 years ago

Paul Hud­son spells out new $6.15B tech­nol­o­gy play as Sanofi goes drug hunt­ing in on­col­o­gy, im­munol­o­gy

4 years ago

Once her­ald­ed as its next big cash cow, Jazz takes a marked down price for not-so-hot sleep dis­or­der drug

4 years ago
Pharma

Spe­cial­ty phar­ma play­er snaps up Aca­cia and its 2 drugs for a handy $100M

4 years ago

Drug dis­cov­ery spe­cial­ists at Lig­and take their an­ti­body biz pub­lic via SPAC, aim­ing to build $850M com­pa­ny

4 years ago
First page Previous page 61626364656667 Next page Last page
A service from the Financial Times